Shiqing Xu

Has grant

Assistant Professor

Texas A&M University

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Shiqing Xu is an Assistant Professor at Texas A&M University, located in the United States. His research focuses on the development of novel therapeutic agents, particularly in the areas of acute myeloid leukemia and SARS-CoV-2 inhibitors. Recent publications include significant advancements in PROTAC degraders for viral proteases and innovative approaches to peptide cyclization for enhanced neutralizing activity.

Recent Grants

Grant: Close

Development of PROTACs Targeting Papain-like Protease as Broad-Spectrum Anti-Coronavirus Therapeutics

Open Date: 2022-05-26

Close Date: 2024-04-30

Grant: Close

The Development of Reversible Covalent PROTAC Technology as a New Anti-COVID-19 Strategy

Open Date: 2021-06-25

Close Date: 2023-05-31

Articles (17)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (4)

Sankar Chaki

Texas A&M University

UNITED STATES

View details

Xin Yan

Assistant Professor

Texas A&M University

UNITED STATES

View details

wenshe Liu

Harry E. Bovay, Jr. Endowed Chair and Professor in Chemistry

Texas A&M University

UNITED STATES

View details

Carol Fierke

Provost and Executive Vice President for Academic Affairs, and Professor of Biochemistry

Brandeis University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Shiqing Xu

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (17)

Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease

Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors

Leveraging a Phage-Encoded Noncanonical Amino Acid: A Novel Pathway to Potent and Selective Epigenetic Reader Protein Inhibitors

BRD4354 Is a Potent Covalent Inhibitor against the SARS-CoV-2 Main Protease

Prioritization of Eleven-Nineteen-Leukemia Inhibitors as Orally Available Drug Candidates for Acute Myeloid Leukemia

A Novel Y-Shaped, S–O–N–O–S-Bridged Cross-Link between Three Residues C22, C44, and K61 Is Frequently Observed in the SARS-CoV-2 Main Protease

An amber-encoding helper phage for more efficient phage display of noncanonical amino acids

A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main Protease

Phage‐assisted, active site‐directed ligand evolution of a potent and selective histone deacetylase 8 inhibitor

Novel Regioselective Approach to Cyclize Phage-Displayed Peptides in Combination with Epitope-Directed Selection to Identify a Potent Neutralizing Macrocyclic Peptide for SARS-CoV-2

A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals

Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir

A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals

A Reversible Chemogenetic Switch for Chimeric Antigen Receptor T Cells**

Cover Picture: A Reversible Chemogenetic Switch for Chimeric Antigen Receptor T Cells (Angew. Chem. Int. Ed. 10/2022)

Titelbild: A Reversible Chemogenetic Switch for Chimeric Antigen Receptor T Cells (Angew. Chem. 10/2022)

Evaluation of SARS-CoV-2 Main Protease Inhibitors Using a Novel Cell-Based Assay

Collaborators (4)

Sankar Chaki

Xin Yan

wenshe Liu

Carol Fierke

Make your next move.